Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hood River Capital Management David Swank | 1,738,613 | $141,818,662 | +5% | 1.03% |
| 2. | D E Shaw D. E. Shaw | 1,548,919 | $126,345,323 | -6% | 0.06% |
| 3. | Tang Capital Management Kevin C. Tang | 1,500,000 | $122,355,000 | 5.56% | |
| 4. | Driehaus Capital Richard Driehaus | 1,440,107 | $117,469,528 | +42% | 0.68% |
| 5. | Armistice Capital Steven Boyd | 1,071,395 | $87,393,690 | -49% | 1.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | $198,736.23 | 33,700 | 2023-12-12 | Filing | |
| $32.48 | 10,000 | $324,846.00 | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | $1,999,995.00 | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | $337,230.00 | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | $12,460.00 | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.57 | 10,292 | $705,722.44 | 383,868 | 2026-08-04 | Filing | |
| $80.35 | 3,494 | $280,742.90 | 83,986 | 2026-07-14 | Filing | |
| $90.00 | 5,834 | $525,060.00 | 21,813 | 2026-07-09 | Filing | |
| $90.00 | 10,000 | $900,000.00 | 21,813 | 2026-07-09 | Filing | |
| $90.25 | 2,464 | $222,376.00 | 60,299 | 2026-07-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,964,554 | $1,139,088,671 | 0.02% | |
| 2. | 7,746,415 | $631,875,072 | 5.39% | |
| 3. | 7,236,402 | $590,181,512 | 0.24% | |
| 4. | 4,928,111 | $401,986,014 | 0.02% | |
| 5. | 4,598,952 | $375,136,515 | 0.01% |
News See All
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics' First Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's conference is being recorded.
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results
PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics, Inc.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Fourth Quarter and Full Year 2025 Earnings Conference Call.
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves
TheFly reported on January 8 that Morgan Stanley raised its price target on PTCT to $90 from $78 and reiterated an Overweight rating.
15 High Growth Mid-Cap Stocks to Buy
The US stock market is shifting as President Trump reinforces his “America First” agenda through subsidies and incentives aimed at boosting domestic manufacturing.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded.
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.